FDA-Approved Peptides List 2026: A Physician’s Regulatory Landscape

Why a Consolidated View Matters

The peptide regulatory landscape is not organized in a way that’s easy for practicing physicians to navigate. Some peptides are FDA-approved under brand names; others are accessible through compounding under specific frameworks; others are not legitimately accessible in U.S. clinical practice. A consolidated view helps match patient questions to the right answer quickly.

This post is a current-state overview. Because the landscape changes, physicians should verify status against the most recent FDA action for any specific substance they plan to prescribe.

FDA-Approved Peptide Therapies (Selected)

Several peptides are FDA-approved under commercial brand names for specific indications:

[Semaglutide](https://newtropin.com/peptides/semaglutide/) (Ozempic, Wegovy, Rybelsus). GLP-1 agonist. Type 2 diabetes, weight management.

[Tirzepatide](https://newtropin.com/peptides/tirzepatide/) (Mounjaro, Zepbound). Dual GLP-1 / GIP agonist. Type 2 diabetes, weight management, sleep apnea in obesity.

Liraglutide (Victoza, Saxenda). GLP-1 agonist. Type 2 diabetes, weight management.

[Tesamorelin](https://newtropin.com/peptides/tesamorelin/) (Egrifta). GHRH analog. HIV-associated lipodystrophy visceral fat reduction.

Glucagon (various). Diabetic emergencies.

Calcitonin (Miacalcin). Osteoporosis, hypercalcemia.

Synthetic oxytocin (Pitocin). Obstetric indications.

Insulin and insulin analogs. Diabetes management — multiple products.

This list is illustrative rather than exhaustive. Many peptides have FDA approval for narrow indications and practical physician practice involves them routinely.

Peptides With Complex Compounding Status

Several commonly discussed peptides are not FDA-approved but have been accessible through 503A compounding channels. Their specific status continues to evolve:

[BPC-157](https://newtropin.com/peptides/bpc/). Not FDA-approved. Compounding status affected by the April 2026 action; current verification required.

[TB-500](https://newtropin.com/peptides/tb-500/). Not FDA-approved. Similar compounding status considerations.

[CJC-1295](https://newtropin.com/peptides/cjc-and-ipamorelin/) / ipamorelin. Not FDA-approved as commercial pharmaceuticals; commonly accessed through compounding.

[GHK-Cu](https://newtropin.com/blog/ghk-cu-the-peptide-regenerative-and-anti-aging/). Not FDA-approved; compounding access has varied.

[Epitalon](https://newtropin.com/blog/epitalon-the-longevity-peptide-revolutionizing-anti-aging-medicine/). Not FDA-approved; compounding access varies with PCAC cycles.

Enclomiphene. Approval status has evolved through multiple cycles; current specific formulation status requires verification.

Each of these substances has a specific regulatory history worth tracking individually.

Peptides Without Legitimate U.S. Clinical Access

Several peptides that appear in patient conversation have no legitimate U.S. clinical access pathway:

Melanotan II. Not FDA-approved. Has been associated with patient safety concerns from unregulated use. Not on 503A list.

[DSIP](https://newtropin.com/peptides/delta-sleep-inducing-peptide/) (Delta Sleep-Inducing Peptide). Not FDA-approved. Research peptide; not on 503A list.

[Semax](https://newtropin.com/peptides/semax/). Not FDA-approved; research peptide.

MOTS-c. Not FDA-approved; status on 503A list has varied.

Dihexa. Research compound; not FDA-approved.

[SLU-PP-332](https://newtropin.com/blog/slu-pp-332-the-exercise-mimetic-revolutionizing-metabolic-medicine/). Research compound; not FDA-approved (see dedicated post earlier in this library).

Retatrutide. Investigational drug in clinical development; not available through legitimate compounding.

Patients encountering these substances in consumer conversation should be directed toward legitimate alternatives for the underlying clinical concern, and counseled on the risks of research-grade sourcing.

Why Patients Encounter Non-Approved Peptides Anyway

Several factors drive patient interest in substances without legitimate U.S. access:

• International availability (some jurisdictions have different regulatory frameworks)
• Biohacker and longevity community discussion
• Research literature that frames investigational compounds aspirationally
• Marketing by businesses operating outside the regulatory framework
• Social media coverage that is often ahead of clinical reality

The Counseling Framework

For any patient question about a peptide:

1. Identify the specific substance — sometimes patients describe compounds imprecisely
2. Verify current regulatory status against the FDA record
3. Understand the patient’s underlying goal — what are they trying to address?
4. Offer legitimate alternatives where they exist
5. Counsel on safety for patients tempted by non-regulated sources

Key Takeaways

• Multiple peptides have FDA approval for specific indications.
• A larger number of peptides have been accessible through 503A compounding, with status that has evolved.
• Several peptides that appear in patient conversation have no legitimate U.S. clinical access.
• Current status for any specific peptide requires verification against the most recent FDA record.
• Effective patient counseling combines regulatory accuracy with honest engagement with the underlying clinical goal.

Frequently Asked Questions

What peptides are FDA-approved in 2026?

A number of peptides are approved for specific indications. Common ones include semaglutide, tirzepatide, liraglutide, tesamorelin, and various insulin analogs. The approval landscape continues to evolve.

Is DSIP FDA-approved?

No. DSIP is a research peptide without FDA approval or 503A listing.

What’s the FDA status of Melanotan II?

Not approved. Has been associated with patient safety issues from unregulated use.

Where can I verify current peptide regulatory status?

The FDA website, Federal Register notices, and PCAC meeting records are the authoritative sources.